Durable Response of Dabrafenib, Trametinib, and Capmatinib in an NSCLC Patient With Co-Existing BRAF-KIAA1549 Fusion and MET Amplification: A Case Report

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2022, Vol.12, p.838798-838798
Main Authors: Chou, Yun-Tse, Lin, Chien-Chung, Lee, Chung-Ta, Pavlick, Dean C, Su, Po-Lan
Format: Report
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.838798